Licensing of the GS Gene Expression System™ expands OBT’s access to world-class technologies for its maturing pipeline of therapeutic antibodies in oncology, and demonstrates its commitment to strengthening both antibody production and preclinical capabilities.
“We are delighted to have access to Lonza’s GS Gene Expression System™ as an addition to our technology portfolio”, commented Tom Boone, who recently joined OBT as Senior Vice President, Protein Sciences following 28 years at Amgen.
Boone continued, “The speed and ease of use of the GS System™ will aid the rapid selection of high-producing cell lines and accelerate the production and development of our most promising anticancer agents.”
“We are proud to have our GS Gene Expression System™ contribute to Oxford BioTherapeutics innovation in cancer research,” said Janet White, Head of Development Services.
White continued, “We look forward to supporting OBT’s efforts to expand and develop its pipeline of promising new oncology drugs.”
OBT has a broad pipeline of preclinical antibody programs directed to novel cancer targets that it has identified using its OGAP® proteomic database.